CANY
ATRS

Caxton Associates (New York)’s Antares Pharma, Inc. ATRS Stock Holding History

Caxton Associates (New York)’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-51,085
Closed -$204K – 489
2020
Q4 		$204K Buy
+51,085
New +$165K 0.01% 115
2020
Q3 		– Sell
-34,165
Closed -$94K – 563
2020
Q2 		$94K Buy
+34,165
New +$95.3K 0.01% 424

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Caxton Associates (New York)'s ATRS Position: Q1 2021 in Review

Caxton Associates (New York) sold out of Antares Pharma, Inc. (ATRS) in Q1 2021, closing a stake of 51,085 shares — an estimated $204K sold.

Caxton Associates (New York) first reported a position in ATRS in Q2 2020 and held it in 2 quarters. The position peaked at $204K in Q4 2020. 171 funds tracked by Wall St. Rank hold ATRS as of Q1 2021.

  • Caxton Associates (New York) reported no remaining Antares Pharma, Inc. position as of Q1 2021 after selling out during the quarter.
  • Caxton Associates (New York) sold 51,085 Antares Pharma, Inc. shares in Q1 2021, an estimated $204K.
  • Caxton Associates (New York) first reported a position in Antares Pharma, Inc. in Q2 2020 and held it in 2 quarters.
  • Caxton Associates (New York)'s Antares Pharma, Inc. position peaked at $204K in Q4 2020.
  • 171 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2021.

Based on Caxton Associates (New York)'s 13F filing for Q1 2021, filed 17 May 2021.